BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 24035502)

  • 21. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
    Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
    Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
    Canbay E; Mizumoto A; Ichinose M; Ishibashi H; Sako S; Hirano M; Takao N; Yonemura Y
    Ann Surg Oncol; 2014 Apr; 21(4):1147-52. PubMed ID: 24356799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aggressive locoregional management of recurrent peritoneal sarcomatosis.
    Baumgartner JM; Ahrendt SA; Pingpank JF; Holtzman MP; Ramalingam L; Jones HL; Zureikat AH; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2013 Mar; 107(4):329-34. PubMed ID: 23386388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment.
    Valle M; Federici O; Carboni F; Toma L; Gallo MT; Prignano G; Giannarelli D; Cenci L; Garofalo A
    Eur J Surg Oncol; 2014 Aug; 40(8):950-6. PubMed ID: 24246609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.
    Ceelen WP; Van Nieuwenhove Y; Van Belle S; Denys H; Pattyn P
    Ann Surg Oncol; 2012 Jul; 19(7):2352-9. PubMed ID: 20039210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
    J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
    Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y
    Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality.
    Cripe J; Tseng J; Eskander R; Fader AN; Tanner E; Bristow R
    Ann Surg Oncol; 2015 Feb; 22(2):655-61. PubMed ID: 25155402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study.
    Cascales-Campos PA; López-López V; Muñoz-Casares FC; Feliciangeli E; Torres Melero J; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Gil J
    Surg Oncol; 2016 Jun; 25(2):111-6. PubMed ID: 27312037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
    Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genitourinary resection at the time of cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis is not associated with increased morbidity or worsened oncologic outcomes: a case-matched study.
    Leapman MS; Jibara G; Tabrizian P; Franssen B; Yang MJ; Romanoff A; Hall SJ; Palese M; Sarpel U; Hiotis S; Labow D
    Ann Surg Oncol; 2014 Apr; 21(4):1153-8. PubMed ID: 24322531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience.
    Königsrainer I; Horvath P; Struller F; Grischke EM; Wallwiener D; Königsrainer A; Beckert S
    Langenbecks Arch Surg; 2014 Jun; 399(5):589-94. PubMed ID: 24817542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status.
    Ihemelandu CU; McQuellon R; Shen P; Stewart JH; Votanopoulos K; Levine EA
    Ann Surg Oncol; 2013 Oct; 20(11):3519-26. PubMed ID: 23748607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
    Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P
    Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
    Piso P; Slowik P; Popp F; Dahlke MH; Glockzin G; Schlitt HJ
    Ann Surg Oncol; 2009 Aug; 16(8):2188-94. PubMed ID: 19408049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy associated toxicity in treatment of peritoneal carcinomatosis].
    Mancebo-González A; Díaz-Carrasco MS; Cascales-Campos P; de la Rubia A; Gil Martínez J
    Farm Hosp; 2012; 36(2):60-7. PubMed ID: 21514864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of operative morbidity in a single center initial experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Graziosi L; Mingrone E; Marino E; Cavazzoni E; Donini A
    Tumori; 2014; 100(1):15-20. PubMed ID: 24675485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
    Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.
    Bakrin N; Cotte E; Golfier F; Gilly FN; Freyer G; Helm W; Glehen O; Bereder JM
    Ann Surg Oncol; 2012 Dec; 19(13):4052-8. PubMed ID: 22825772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.